ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1344	National Cancer Institute	Html	en	How To Handle Withdrawal Symptoms and Triggers When You Decide To Quit Smoking	This fact sheet provides helpful tips related to smoking cessation.	routine smoke breaks 0.282965 smoking effects 0.278771 relaxation techniques 0.313407 nicotine addiction 0.355656 Control Research Branch 0.30123 Yes. Nicotine replacement 0.344131 nicotine withdrawal symptoms 0.36823 urge 0.354906 tips 0.337093 negative feelings 0.295635 Nicotine nasal spray 0.380205 tea 0.279209 Tobacco Control Research 0.298555 things 0.265705 tobacco smoke 0.262113 nicotine replacement therapy 0.347084 drinking coffee 0.292775 highly dependent smokers 0.261935 daily life 0.289451 Smoking Quitline 0.271985 Step-by-Step Quit Guide 0.333256 nicotine replacement products 0.922705 help quitting tobacco 0.287795 nicotine replacement product 0.346885 smoking increase 0.274802	weight gain 0.385772 smokers 0.365077 counter weight gain 0.289631 nicotine cravings 0.53551 nicotine doses 0.315612 common negative feelings 0.293918 smoking 0.59993 nicotine lozenge 0.318321 nicotine inhaler 0.328106 nicotine travels 0.313333 nicotine level drops 0.347286 chews nicotine gum 0.341989 people 0.407906 strong urge 0.298124 physical activity 0.320031 people smoking 0.295038 nicotine gum 0.386182 nicotine patch 0.339006 withdrawal symptoms 0.655994 common withdrawal symptoms 0.360181 coffee 0.312007 smoking cessation trials 0.292819 Occasional mild cravings 0.284899 time 0.303672	CLICK HERE
1420	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	hereditary prostate cancer 0.542395 prostate biopsy 0.533126 dutasteride group vs 0.459041 skin cancer 0.446356 prostate cancer period 0.528407 cancer mortality rates 0.459369 prostate volume subgroups 0.508967 Prostate Cancer Events 0.558338 finasteride group versus 0.448086 rat ventral prostate 0.516053 high-grade tumors 0.479135 high-grade cancer 0.454168 prostate cancer-specific mortality 0.525559 occult prostate cancer 0.561891 high-grade prostate cancer 0.548137 prostate preventive effects 0.507979 relative risk reduction 0.446967 radical prostatectomy 0.460894 prostate cancer mortality 0.534065 prostate cancer chemoprevention 0.531007 dietary fat 0.445789 men 0.4492 Cancer Events trial 0.451937 negative prostate biopsy 0.515564	digital rectal examination 0.454846 dutasteride group 0.460003 fat intake 0.450377 Cancer Prevention Trial 0.500983 prostate digital 0.500034 prostate cancer risk 0.564597 placebo group 0.469544 incident prostate cancer 0.532469 Cancer Events study 0.447937 prostate volume 0.517049 absolute risk reduction 0.495169 low biologic risk 0.447169 finasteride group 0.448145 prostate cancer 0.910772 Gleason 0.458954 clinical prostate cancer 0.556069 pancake-appearing prostate 0.508749 Prostate Cancer Prevention 0.595277 prostate cancer. 0.505972 prostate cancer death. 0.562581 statistically significant difference 0.470146 prostate cancers 0.559985 human prostate cancer 0.538634	CLICK HERE
1495	National Cancer Institute	Html	en	Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of hairy cell leukemia.	purine analog therapy 0.544174 BRAF inhibitor 0.537215 overall response rate 0.600065 cell leukemia patients 0.629349 purine analogs 0.574118 Hot Flashes 0.53761 complete remission rate 0.547966 long-term follow-up 0.53699 long term follow-up 0.54098 Tiacci et al. 0.545702 Foucar MK 0.540256 classic-form hairy cell 0.592078 cell leukemia variants. 0.563299 peripheral blood counts 0.541349 Pettirossi et al. 0.546064 median overall survival 0.57455 9-year median follow-ups 0.545986 patients 0.634056 continuous infusion 0.540582 multicenter studies 0.537514 VH4-34+ hairy cell 0.567746 B-cell lymphomas 0.539052 Rosenberg et al. 0.545728 Natl Cancer Inst 0.537773	hairy-cell leukemia 0.564359 Night Sweats 0.538245 et al. 0.547621 median treatment-free survival 0.574134 partial remission rate 0.543701 stable partial remission 0.545722 cladribine 0.537399 complete remissions 0.537086 one-time continuous infusion 0.53916 comparable response rates 0.548208 treatment option 0.539331 median follow-up 0.54766 potential increased risk 0.575127 cell leukemia variant 0.57205 overall response rate. 0.539597 complete response rate 0.636139 Abstract 0.548918 hairy cell leukemia 0.918712 Clin Oncol 0.592807 subcutaneous injections 0.544059 PDQ summary 0.53807 cell leukemia variants 0.563543 previously untreated patients 0.548389 standardized incidence ratio 0.536889	CLICK HERE
1736	National Cancer Institute	Html	en	Surgery to Reduce the Risk of Breast Cancer	A fact sheet that describes mastectomy and salpingo-oophorectomy, two surgeries that may be used to reduce breast cancer risk in women at very high risk, and nonsurgical options.	Surgical Adjuvant Breast 0.509427 breast cancer talk 0.520216 primary breast cancer 0.51166 breast reconstruction surgery 0.528802 radiation-associated breast cancer 0.517996 breast health specialist 0.49326 Breast cancer phenotype 0.510792 Breast Cancer Research 0.511066 early-stage breast cancer 0.509281 breast screening 0.478516 cancer risk reduction 0.514817 bilateral risk-reducing mastectomy 0.474208 bilateral breast cancer 0.543505 ovarian cancer 0.506899 frequent breast cancer 0.518031 clinical breast examinations 0.496735 normal breast functions 0.496662 high risk 0.488512 invasive breast cancer 0.560151 Clinical Oncology 0.486116 primary breast cancers 0.493314 BRCA2 mutation carriers 0.492894 contralateral breast cancer 0.595168 women 0.553369	early breast cancer 0.515841 J. Prophylactic mastectomy 0.474619 appropriate cancer prevention 0.465287 prophylactic bilateral mastectomy 0.491713 breast cancer susceptibility 0.516869 breast cancer surgery 0.554904 prophylactic surgery 0.485463 breast cancers 0.51424 greatest breast cancer 0.535025 breast tissue 0.513481 Cancer Risk Assessment 0.465659 ovarian cancer risk 0.465289 breast surgeons 0.489292 postmenopausal women 0.468075 breast cancer risk 0.685989 breast cancer 0.963464 bilateral prophylactic mastectomy 0.680206 Breast Cancer Trialists 0.509574 prophylactic mastectomy 0.701891 Bilateral prophylactic salpingo-oophorectomy 0.47763 contralateral prophylactic mastectomy 0.553604 strong family history 0.509663 breast cancer-associated mutations 0.511851 et al 0.584443	CLICK HERE
1774	National Cancer Institute	Html	es	Fatiga (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de la fatiga, una afección caracterizada por extremo cansancio e incapacidad para funcionar por la falta de energía, que a menudo se observa como una complicación del cáncer y su tratamiento.	adjuvant chemotherapy 0.23884 Cancer patients as 0.267855 cáncer respalda 0.229838 Breitbart W 0.226519 frase cansancio 0.380985 cancer-related fatigue 0.694477 FossÃ¥ SD 0.231004 critical appraisal 0.229895 Nail LM 0.242438 tripart assessment survey 0.229866 Fatigue Coalition 0.248097 Sin embargo 0.226985 Bower JE 0.361676 National Comprehensive Cancer 0.433137 Supportive Oncology 0.240439 Jacobsen PB 0.225244 Cancer Res 0.298674 Fatigue after treatment 0.230762 Radiat Oncol Biol 0.235818 Supportive Oncology Updates 0.236977 Hematol Oncol Clin 0.226159 Fatigue Symptom Inventory 0.230776 Support Care 0.298981 Ganz PA 0.346159 survivors with persistent 0.230866	Comprehensive Cancer Network 0.433487 patients with 0.336679 Donovan KA 0.225133 Pain Symptom Manage 0.518651 Cella D 0.246025 patients treated with 0.224435 Ancoli-Israel S 0.229262 Oncol Nurs Forum 0.973332 citocinas proinflamatorias 0.262356 Care Cancer 0.446044 Portenoy RK 0.231388 Procrit Study Group 0.227164 menor cansancio 0.370471 breast carcinoma survivors 0.265734 patients receiving 0.226133 Clin Oncol 0.504505 Oncol Biol Phys 0.236851 individual with 0.229384 research literature investigating 0.225358 long-term breast carcinoma 0.246503 early stage breast 0.235969 Lee Fatigue Scale 0.226512 cancer patient 0.800328 término cansancio 0.373768	CLICK HERE
1960	National Cancer Institute	Html	es	Tratamiento del sarcoma uterino (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del sarcoma uterino.	estadios iva 0.401059 sarcoma uterino causa 0.406591 siguientes procedimientos 0.403992 Estadio IA 0.402022 estadio iv 0.408854 cáncer.ampliar cistoscopia 0.401375 siguientes aspectos 0.404454 Estadio IB 0.402046 estadio ii 0.409805 útero forma 0.405141 Estadio IIIB 0.402011 Estadio IIIC 0.402019 estadios ia 0.401093 vía oral 0.40093 Estadio IIIA 0.402062 rayos x 0.401181 ondas sonoras 0.401284	National Cancer Institute 0.400945 estadios iiia 0.401156 siguientes riesgos 0.400687 áreas anormales.ampliar examen 0.402099 Instituto Nacional 0.401682 PDQ Tratamiento 0.411733 ecograma.ampliar ecografía 0.401623 Physician Data Query 0.403425 último panel 0.401341 estadio iii 0.406282 cuello uterino 0.559914 histerectomía abdominal 0.405298 sarcoma uterino 0.996876 cáncer quizás 0.40452 Estadio IVB 0.402 Estadio IVA 0.401945 extirpa tanta masa 0.402241	CLICK HERE
1965	National Cancer Institute	Html	es	Tratamiento del tumor de Wilms y otros tumores renales infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del tumor de Wilms y otros tumores renales infantiles.	carcinoma mioepitelial renal 0.526401 siguientes procedimientos 0.505279 siguientes aspectos 0.505599 efectos secundarios meses 0.505495 siguientes síndromes 0.506829 siguientes razones 0.503795 rayos x 0.510267 niño ayuda 0.504738 estadio v 0.504623 tumores benignos 0.514918 sustancia llamada gadolinio 0.50702 tumores renales 0.951588 tumor renal 0.637779 pelvis renal 0.507303 alta potencia 0.509261 cánceres renales 0.508824 siguientes enfermedades 0.50611 nefroblastomatosis perilobular hiperplásica 0.509412 Antecedentes familiares 0.504021 vejiga almacena 0.505429 siguientes estadios 0.504745 riñón.ampliar ecografía 0.506308 células madre 0.544993 problemas renales 0.514442	adultos jóvenes 0.513748 estadio iv 0.508345 cabo ensayos 0.506023 cuerpo.ampliar anatomía 0.504995 pequeña cantidad 0.51696 estadio ii 0.508321 túbulos renales 0.518212 ondas sonoras 0.510366 efectos tardíos 0.540359 escáner.ampliar exploración 0.503685 PDQ Efectos tardíos 0.519051 Von Hippel-Lindau 0.513101 PDQ Tratamiento 0.517805 determinados cambios 0.504218 nefroma mesoblástico congénito 0.582259 siguientes signos 0.506344 tirosina cinasa 0.506394 siguientes factores 0.505365 siguientes situaciones 0.504547 gen smarcb1 0.504862 células renales 0.823203 Wilms Tumor 0.52815 gran crecimiento 0.51167 Childhood Kidney Cancers 0.504322	CLICK HERE
2029	National Cancer Institute	Html	es	Prevención del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	Sestak I 0.314213 Methods Mol Biol 0.309681 menor incidencia 0.315649 Breast Cancer Surveillance 0.32247 largo plazo 0.325123 Risk Calculator 0.330192 Cuzick J 0.314017 breast cancer prevention 0.340448 útero intacto 0.328063 Estados Unidos 0.337849 menor riesgo 0.381674 cancer prevention trial 0.330827 Women's Health Initiative 0.311811 principal factor 0.31767 Health Initiative 0.316067 from benign breast 0.320129 Breast density 0.313434 lobular breast 0.315708 English record linkage 0.310983 hormonas estrógeno 0.31642 health study 0.316005 benign breast 0.353338 Cancer Res Treat 0.315355 Cancer Risk Assessment 0.316082 Epidemiol Biomarkers Prev 0.309854	enfermedad proliferativa benigna 0.311069 Goss PE 0.314786 antecedentes familiares 0.49279 Breast Risk Calculator 0.318395 prospective cohort study 0.311422 breast cancer risk 0.370651 reducción promedio 0.315263 breast cancer 0.951386 cardiopatía coronaria 0.328283 riesgos instantáneos 0.314306 IBIS-I breast 0.313331 risk factor 0.343815 mujeres portadoras 0.329041 Cancer Surveillance System 0.312955 IBIS Breast Cancer 0.320333 heritable risk factor 0.311842 Risk Calculator Tool 0.311 Reino Unido 0.311996 Women’s Health Initiative 0.309787 Breast Cancer Referral 0.321555 parenchymal patterns as 0.309616 Otro estudio 0.316688 Breast Cancer Res 0.357313 mujeres jóvenes 0.346647	CLICK HERE
2069	National Cancer Institute	Html	es	Enfermedad de Paget de seno	Hoja informativa sobre la enfermedad de Paget de seno, un tipo poco común de cáncer que algunas veces se llama enfermedad de Paget del pezón o enfermedad de Paget de mama.	Lippincott Williams 0.227873 Tumor Characteristics 0.23784 Eisner MP 0.227823 cáncer invasor 0.852818 afecciones benignas 0.232299 Cody HS 0.226638 Female Breast 0.245015 posibles tumores 0.243494 long-term follow-up study 0.244429 Breast Cancer Research 0.268606 siglo xix sir 0.249073 breast-conserving therapy 0.228801 Lippman ME 0.226791 ganglios linfáticos centinela 0.294176 afección benigna 0.309089 SEER Program 0.276615 Kanitakis J 0.22651 estadio i 0.22947 Hasson D 0.226314 European Institute 0.226377 Keel GE 0.226988 PubMed Abstract 0.996634 Haffty BG 0.225876 clinical presentation 0.228015 Therapeutic options 0.226841	with radiotherapy 0.228051 Tucker SL 0.226414 Paget mamaria 0.499743 estadio iv 0.228625 End Results 0.22623 Griffith KA 0.226914 signo revelador 0.231703 proteína her2 0.228884 National Cancer Institute 0.247867 4th ed 0.228822 Sosnovskikh I 0.226721 Ries LAG 0.280943 edad promedio 0.227469 Breast Journal 0.241614 Osborne CK 0.226941 Sir James Paget 0.694935 Cancer Survival Among 0.251885 estadio iii 0.228362 Gatti G 0.22751 Retrieved April 0.227819 sentinel lymph 0.278815 European Academy 0.22756 extramammary paget 0.443981 Dimaio DJ 0.226799	CLICK HERE
3656	National Cancer Institute	Html	en	David Q. Matus, Ph.D.	David Matus studies cellular invasion--a characteristic behavior of metastatic cancer cells--in an evolutionary context.	colon carcinoma cells 0.575003 anchor cell invasion 0.641108 basement membrane 0.798484 transcription factors 0.55171 cell lines 0.544877 Martindale lab 0.540411 cellular basement membrane 0.610463 basement membranes 0.590872 anchor cell 0.729012 reproductive tract 0.559366 graduate school 0.537018 invasion process 0.549999 deep evolutionary roots 0.554576 different nematode species 0.556072 small translucent worm 0.572459 sea anemones 0.537853 Dr. Matus 0.992838 independent research careers 0.559323 genetic control 0.536692 dense sheet-like layer 0.561929 connective tissue underneath 0.560757 —a systematic method 0.560107 uterine cells 0.552149 Caenorhabditis elegans 0.544264 basic biological processes 0.563833	scientist—while training dolphins 0.567297 evolutionary developmental biology 0.55366 vulval cells 0.554372 academic lineage—a trace 0.553945 individual genes 0.558466 Mark Q. Martindale 0.628065 science fair project 0.55475 Stony Brook University 0.569431 metastatic cancer cells 0.596221 mitotic cells 0.54782 scientific career—and 0.537464 anchor cell dividing 0.581016 invasive cell 0.543064 programmed cell death 0.577561 normal cells 0.556326 New York 0.537757 C. elegans 0.565408 anchor cell invasion—and 0.584387 David Q. Matus 0.656523 Cell Biology Department 0.584431 cellular invasion 0.583572 potential drug targets 0.557542 cell behaviors 0.541546 Dr. Martindale 0.549501	CLICK HERE